April 2 (Reuters) - Dare Bioscience Inc:
* DARÉ BIOSCIENCE, INC. REPORTS 2017 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE
* DARE BIOSCIENCE - INTENDS TO COMMUNICATE WITH U.S. FDA IN MID-2018 REGARDING PHASE 2B STUDY OF TOPICAL SILDENAFIL
* ANTICIPATES COMMENCING A PHASE 2B STUDY OF TOPICAL SILDENAFIL IN Q4 OF 2018 Source text for Eikon: Further company coverage: